play a key role in the competition between the two concomitant immune responses [1] . Thus, we postulate that in our patient, the psoriatic inflammation antagonized the inflammatory mechanism operating in AA [5] . The term "duelling cytokines" has been proposed to describe these complex interactions [6] . In our experience and that of others, psoriasis is less common among DS individuals [1] [2] [3] , whereas AA is rather frequently noted and is often severe [1, 2] . Prior to our observation, only one case of a 20-year-old man with DS, presenting the Renbök phenomenon, has been described. AA occurred first and was then followed by psoriasis [6] . Conversely, in a young woman, remission of psoriasis and induction of AA was observed; the reappearance of psoriasis was then accompanied by hair growth [5] .
In conclusion, individuals with DS may suffer from several dermatoses. The Renbök phenomenon, however, is a rarely observed and intriguing event. Azathioprine combination therapy for steroid-refractory hepatic immune systemrelated adverse events Enhancement of anti-tumour immunity has led to substantial progress in the treatment of melanoma. Two types of immune checkpoint inhibitors, ipilimumab, targeting cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), and pembrolizumab and nivolumab, targeting programmed cell death-1 (PD-1), are now available. Treatment with these agents can cause immune systemrelated adverse events (IRAEs) that manifest as pneumonitis, colitis, pancreatitis, hypothyroidism or hepatitis (i.e. hepatic IRAE) [1] [2] [3] . Nivolumab indications for advanced malignancies, in addition to unresectable or metastatic melanoma, including non-small cell lung cancer, renal cell carcinoma and Hodgkin lymphoma, reveal a potential increase in IRAEs. The majority of IRAEs can be managed with steroids; those refractory to steroid treatment can become life-threatening [4] [5] [6] . Although the purine antagonist mycophenolate mofetil (MMF) is recommended by its manufacturer for steroid-refractory hepatic IRAE [4] , the supporting evidence is limited [5] . The American Association for the Study of Liver Diseases (AASLD) guidelines recommend the purine antagonist azathioprine (AZA) for treatment of steroid-refractory autoimmune hepatitis (AIH) cases, as an evidence-based regimen [7] . Herein, we present [6] . The patient was admitted, nivolumab was stopped, and 2 mg/kg/day of intravenous methylpredonisolone (IVMP) was started. As the liver injury was refractory to high-dose IVMP, including pulse therapy ( figure 1D ), coadministration of oral AZA with a maximum dose of 100 mg/day was started ( figure 1D) . After a month, the liver enzyme levels were normal (AST: 15 U/L; ALT: 30 U/L) and tumour size had increased ( figures 1E-G) . The AASLD guidelines for treatment of AIH recommend AZA as the first choice for steroid refractory cases [7] , and MMF is considered as an alternative treatment for patients who did not previously tolerate AZA [8] [9] [10] . Indeed, there is evidence that AZA-intolerant patients may have higher response rates to MMF than patients refractory to AZA, suggesting that MMF is not always an effective alternative to AZA [8] . Similarly, the evidence that clearly shows the superiority of MMF over AZA in steroid-refractory IRAE is limited [5] , despite the recommendation of MMF for steroid-refractory IRAE hepatitis by the manufacturer of nivolumab [4] . Also, the price of MMF at 2 g/day is approximately seven times higher than that of AZA at 100 mg/day. Consequently, we propose that AZA is considered as a legitimate alternative to MMF for steroid-refractory hepatic IRAEs. To the best of our knowledge, this is the first report of a hepatic IRAE successfully managed with AZA. Additional evidence will permit developing an accepted strategy for IRAE management.
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Kazuyo IWAMOTO IgA-mediated leukaemic vasculitis in a patient with rapid progression of myelodysplastic syndrome to acute myeloid leukaemia
Leukaemic vasculitis is extremely rare in patients with myelodysplastic syndrome (MDS). Although an immunoglobulin (Ig) A-mediated mechanism has been speculated to participate in its pathogenesis, detection of IgA deposition by direct immunofluorescence (IF) has not been so far reported [1] . We describe, herein, a case of leukaemic vasculitis in a patient with MDS and clearly show IgA deposits on vessel walls.
A 79-year-old man presented with multiple erythematous plaques on his trunk and limbs. He had developed fever, arthralgia, and multiple erythematous plaques five days before. Physical examination revealed multiple indurated erythematous plaques on his trunk and limbs ( figures  1A, B) . Laboratory work-up revealed neutropenia (white blood cells: 3,300/L) with no atypical lymphocytes and no differentiation to myeloblasts, slight anaemia (haemoglobin: 10.4 g/dL), thrombopenia (platelets: 11.8×10 4 /L), elevated C-reactive protein (11.87 mg/dL), and slightly elevated serum IgA (518 mg/dL). Antiproteinase 3 (PR3)-anti-neutrophil cytoplasmic antibody (ANCA) and anti-myeloperoxidase (MPO)-ANCA were negative. Histopathological examination showed a perivascular infiltrate in the dermis and hypodermis ( figure 1C) . Infiltration of atypical mononuclear cells, in addition to a small subset of neutrophils into the vessel walls, was found ( figure 1D ). Fibrin deposition was also found ( figure 1E ). The vessel walls were disrupted ( figure 1F) . Immunohistochemical examination revealed that the atypical mononuclear cells expressed CD33 and MPO ( figure 1G, H) . Direct IF revealed IgA deposits on the vessel walls ( figure 1I) . A bone marrow biopsy revealed a focal hypocellular marrow. Karyotypic analysis revealed multiple structural and numerical abnormalities, including a deletion of the long arm of chromosome 5. The diagnosis of MDS (unclassifiable) was made. The histopathological finding that the infiltration of atypical CD33+/MPO+ mononuclear cells disrupted vessel walls may imply a diagnosis of leukaemic vasculitis in MDS because no
